Novo Nordisk A/S Class B

Sales Growth and Guidance: Novo Nordisk reported a 10% sales growth for 2025, with a notable operating profit growth of 6%. However, the guidance for 2026 suggests a decline in sales between -5% to -13% at constant exchange rates, primarily impacted by pricing pressures and reduced Medicaid coverage for anti-obesity medications. The clear distinction between U.S. and International Operations growth, with the latter expected to grow mid-single digits while the U.S. faces a projected significant decline, underscores the challenges in the U.S. market.

Impact of Pricing and Competition: The sales decline in the U.S. is mainly driven by price reductions, which stem from the implementation of market access investments and the "Most Favored Nation" (MFN) agreement that will affect pricing landscape. Investors need to be aware of the potential for further competitive pressures and pricing dynamics as the market for GLP-1 medications evolves, especially with the introduction of new competitors.

Launch of Wegovy Pill: The recent approval and launch of the Wegovy oral pill signals a significant opportunity for expanding Novo Nordisk's reach in the obesity market. Early uptake has been strong, with 50,000 prescriptions in the initial weeks, indicating that oral options may broaden the patient base. However, the future performance of Wegovy may influence injectable sales, presenting both a risk and an opportunity for market share dynamics.